#United States #San Diego #Class Action #Robbins LLP #Zoetis Inc.

Zoetis Inc. Faces Class Action Lawsuit

A significant class action lawsuit has been initiated against Zoetis Inc. (NYSA: ZTS), primarily focusing on the alleged misrepresentations made by the company regarding its flagship products. This action, facilitated by the renowned shareholder rights law firm Robbins LLP, seeks to protect the interests of investors who purchased or acquired Zoetis securities between January 14, 2025, and May 6, 2026.

Background of Zoetis Inc.

Zoetis Inc. specializes in animal health, offering a range of products including vaccines and medicines aimed at both livestock and companion animals. The company has built a reputation for quality and innovation in the veterinary sector. However, recent disclosures have raised concerns over its transparency and business practices, particularly regarding two of its prominent products: Librela and Simparica Trio.

Allegations Against Zoetis

According to the lawsuit filed by Robbins LLP, several serious allegations have come to light:
1. Declining Growth for Librela: Reports indicate that the veterinary prescription growth and adoption rates for Librela, a canine pain management treatment, have dropped significantly. This decline follows safety warnings from the FDA, which alarmed many veterinarians regarding potential neurological complications in dogs resulting from the treatment.
2. Market Share Loss for Simparica Trio: The company’s Simparica Trio, a canine parasiticide, has reportedly been losing ground against lower-priced competitors with broader indications. This decline comes within a challenging market environment, further exacerbating the company's troubles.
3. Competition in Dermatology: Zoetis's dermatology products, Apoquel and Cytopoint, are facing fierce competition from newly launched canine treatments, resulting in a considerable market share loss.

The suit claims that these disclosures about the deterioration of the company's product lines revealed the truth behind the alleged misrepresentations. Over the course of various announcements between August 5, 2025, and May 7, 2026, the company expressed that its Companion Animal business's performance was significantly declining, resulting in a lowered full-year financial forecast.

In a dramatic turn of events, the final announcement on May 7, 2026, triggered a staggering 21.5% drop in Zoetis's stock price, dropping from $111.22 to $87.31 in a single day.

Next Steps for Affected Investors

For shareholders who acquired Zoetis securities during the specified period, there may be a possibility to take part in the class action against the company. Interested parties must submit the necessary documentation to assume the role of lead plaintiff by July 27, 2026. This role involves representing other class members throughout the litigation process. However, interested parties are not compelled to take action to qualify for recovery.

Robbins LLP operates on a contingency fee basis; therefore, no upfront fees or expenses will fall to the shareholders. This model underscores the firm's commitment to securing compensation for investors affected by corporate misdeeds.

About Robbins LLP

Established in 2002, Robbins LLP has earned recognition as a leader in shareholder rights litigation. The attorneys here dedicate their efforts to helping investors recover their losses and holding corporate executives accountable when wrongdoing occurs. For those who wish to stay informed about class actions pertaining to Zoetis or seek updates on corporate malfeasance, signing up for alerts from Robbins LLP is advisable.

This class action against Zoetis underscores the crucial role that transparency plays in the financial health of publicly traded companies. As shareholders continue navigating complexities in the investment landscape, vigilance in tracking corporate behavior remains paramount.